Catheter Precision Announces Introduction of the LockeT Product Line into Italy
Catheter Precision (NYSE:VTAK) has announced the successful introduction of its LockeT product line into the Italian market, marking its third European country expansion following France and Germany. The first procedures were successfully conducted at ASST Valle Olona Hospital by Dr. Manuela Bianchi.
The company received its first commercial purchase order from Italian distributor Precise Srl following successful product evaluation. This expansion demonstrates growing market acceptance of LockeT, a device designed to streamline closure after catheter ablation procedures while maintaining cost-effectiveness.
Catheter Precision (NYSE:VTAK) ha annunciato l'ingresso sul mercato italiano della sua linea di prodotti LockeT, segnando la terza espansione europea dopo Francia e Germania. Le prime procedure sono state eseguite con successo presso l'ASST Valle Olona Hospital dalla Dott.ssa Manuela Bianchi.
L'azienda ha ricevuto il primo ordine commerciale dal distributore italiano Precise Srl a seguito di una positiva valutazione del prodotto. Questa espansione testimonia un crescente apprezzamento per LockeT, un dispositivo studiato per semplificare la chiusura dopo gli interventi di ablazione transcatetere, mantenendo al contempo un buon rapporto costi-efficacia.
Catheter Precision (NYSE:VTAK) ha anunciado la introducción en el mercado italiano de su línea de productos LockeT, lo que supone su tercera expansión en Europa tras Francia y Alemania. Los primeros procedimientos se realizaron con éxito en el ASST Valle Olona Hospital por la Dra. Manuela Bianchi.
La compañía recibió su primer pedido comercial del distribuidor italiano Precise Srl tras una evaluación satisfactoria del producto. Esta expansión refleja una creciente aceptación de LockeT, un dispositivo diseñado para agilizar el cierre tras procedimientos de ablación con catéter, manteniendo la rentabilidad.
Catheter Precision (NYSE:VTAK)가 자사의 LockeT 제품군을 이탈리아 시장에 성공적으로 출시했다고 발표했으며, 이는 프랑스와 독일에 이어 세 번째 유럽 진출입니다. 첫 시술은 ASST Valle Olona Hospital에서 마누엘라 비앙키 박사에 의해 성공적으로 진행되었습니다.
제품 평가가 성공적으로 완료된 후 이탈리아 유통사 Precise Srl로부터 첫 상업 주문을 받았습니다. 이번 확장은 카테터 소작(절제) 시술 후 폐쇄 과정을 간소화하면서 비용 효율성을 유지하도록 설계된 LockeT에 대한 시장 수용이 확대되고 있음을 보여줍니다.
Catheter Precision (NYSE:VTAK) a annoncé l'introduction réussie de sa gamme de produits LockeT sur le marché italien, marquant ainsi sa troisième expansion en Europe après la France et l'Allemagne. Les premières procédures ont été réalisées avec succès à l'ASST Valle Olona Hospital par le Dr Manuela Bianchi.
L'entreprise a reçu sa première commande commerciale du distributeur italien Precise Srl après une évaluation concluante du produit. Cette expansion témoigne d'une acceptation croissante de LockeT, un dispositif conçu pour simplifier la fermeture après les procédures d'ablation par cathéter tout en restant rentable.
Catheter Precision (NYSE:VTAK) hat die erfolgreiche Einführung seiner LockeT-Produktlinie auf dem italienischen Markt bekanntgegeben und damit die dritte europäische Expansion nach Frankreich und Deutschland erzielt. Die ersten Eingriffe wurden erfolgreich im ASST Valle Olona Hospital von Dr. Manuela Bianchi durchgeführt.
Das Unternehmen erhielt nach einer erfolgreichen Produktbewertung die erste kommerzielle Bestellung vom italienischen Vertriebspartner Precise Srl. Diese Expansion zeigt eine zunehmende Marktakzeptanz von LockeT, einem Gerät, das den Verschluss nach kathetergestützten Ablationsverfahren vereinfachen und zugleich kosteneffizient bleiben soll.
- Successful expansion into third European market (Italy) following France and Germany
- Receipt of first commercial purchase order from Italian distributor
- Successful clinical evaluation and acceptance by medical professionals
- Growing market penetration following recent CE Mark approval
- None.
First European Purchase Order for LockeT Received
Fort Mill, SC, Sept. 02, 2025 (GLOBE NEWSWIRE) -- – Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced the introduction of LockeT in Italy. Following the first successful procedures and clinical acceptance in France and Germany a successful product evaluation was completed in Italy.
The first procedures in Italy were performed at ASST Valle Olona Hospital, under the expert guidance of Dr. Manuela Bianchi. These initial cases further demonstrate the versatility and clinical value of LockeT across diverse healthcare settings.
After the successful evaluation Catheter Precision received the first commercial purchase order from long-time partner and distributor Precise Srl. This milestone marks the beginning of broader market access and commercial deployment of Catheter Precision’s technologies across the region.
David Jenkins, CEO of Catheter Precision, said, “We are encouraged by the rapid uptake of LockeT acceptance in Europe, the introduction of the product into a third European country so quickly after the CE Mark approval and the first purchase order. The excitement from physicians for LockeT further demonstrates the need for a product that streamlines closure after catheter ablation procedures while remaining cost-effective.”
About LockeT
Catheter Precision’s LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA and has received CE Mark approval.
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC and available at www.sec.gov.
The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
# # #
CONTACTS: Investor Relations 973-691-2000 IR@catheterprecision.com
FAQ
What is the latest European market expansion for Catheter Precision's (VTAK) LockeT product?
Where were the first LockeT procedures performed in Italy?
Who is Catheter Precision's (VTAK) distribution partner in Italy?
What is the primary benefit of Catheter Precision's LockeT device?
Which European markets has Catheter Precision (VTAK) entered with LockeT?
